Last reviewed · How we verify

Intramuscularly administered Ad5-nCoV vaccine

Jiangsu Province Centers for Disease Control and Prevention · FDA-approved active Biologic

Intramuscularly administered Ad5-nCoV vaccine is a viral vector vaccine Biologic drug developed by Jiangsu Province Centers for Disease Control and Prevention. It is currently FDA-approved for COVID-19 prevention in adults.

An adenovirus type 5 (Ad5) vector vaccine delivers the SARS-CoV-2 spike protein gene intramuscularly to stimulate cellular and humoral immune responses against COVID-19.

An adenovirus type 5 (Ad5) vector vaccine delivers the SARS-CoV-2 spike protein gene intramuscularly to stimulate cellular and humoral immune responses against COVID-19. Used for COVID-19 prevention.

At a glance

Generic nameIntramuscularly administered Ad5-nCoV vaccine
SponsorJiangsu Province Centers for Disease Control and Prevention
Drug classviral vector vaccine
TargetSARS-CoV-2 spike protein
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

The Ad5-nCoV vaccine uses a replication-incompetent adenovirus serotype 5 as a viral vector to transport genetic material encoding the SARS-CoV-2 spike protein into host cells. Once inside cells, the spike protein is expressed and presented to the immune system, triggering both CD8+ T-cell and antibody responses. This approach provides protection against SARS-CoV-2 infection and COVID-19 disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intramuscularly administered Ad5-nCoV vaccine

What is Intramuscularly administered Ad5-nCoV vaccine?

Intramuscularly administered Ad5-nCoV vaccine is a viral vector vaccine drug developed by Jiangsu Province Centers for Disease Control and Prevention, indicated for COVID-19 prevention in adults.

How does Intramuscularly administered Ad5-nCoV vaccine work?

An adenovirus type 5 (Ad5) vector vaccine delivers the SARS-CoV-2 spike protein gene intramuscularly to stimulate cellular and humoral immune responses against COVID-19.

What is Intramuscularly administered Ad5-nCoV vaccine used for?

Intramuscularly administered Ad5-nCoV vaccine is indicated for COVID-19 prevention in adults.

Who makes Intramuscularly administered Ad5-nCoV vaccine?

Intramuscularly administered Ad5-nCoV vaccine is developed and marketed by Jiangsu Province Centers for Disease Control and Prevention (see full Jiangsu Province Centers for Disease Control and Prevention pipeline at /company/jiangsu-province-centers-for-disease-control-and-prevention).

What drug class is Intramuscularly administered Ad5-nCoV vaccine in?

Intramuscularly administered Ad5-nCoV vaccine belongs to the viral vector vaccine class. See all viral vector vaccine drugs at /class/viral-vector-vaccine.

What development phase is Intramuscularly administered Ad5-nCoV vaccine in?

Intramuscularly administered Ad5-nCoV vaccine is FDA-approved (marketed).

What are the side effects of Intramuscularly administered Ad5-nCoV vaccine?

Common side effects of Intramuscularly administered Ad5-nCoV vaccine include Injection site pain or swelling, Fever, Fatigue, Headache, Myalgia.

What does Intramuscularly administered Ad5-nCoV vaccine target?

Intramuscularly administered Ad5-nCoV vaccine targets SARS-CoV-2 spike protein and is a viral vector vaccine.

Related